Prognostic Model for Stratification of Radioresistant Nasopharynx Carcinoma to Curative Salvage Radiotherapy
Authors:
- You Quan LiYLYou Quan Li
- Yun Ming TianYTYun Ming Tian
- Sze Huey TanSTSze Huey Tan
- Ming Zhu LiuMLMing Zhu Liu
- Grace KusumawidjajaGKGrace Kusumawidjaja
- Enya H.W. OngEOEnya H.W. Ong
- Chong ZhaoCZChong Zhao
- Terence W.K. TanTTTerence W.K. Tan
- Kam Weng FongKFKam Weng Fong
- Kiattisa SommatKSKiattisa Sommat
- Yoke Lim SoongYSYoke Lim Soong
- Joseph T.S. WeeJWJoseph T.S. Wee
- 20 March 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (9) , 891-899
Abstract
Purpose: To investigate for a prognostic index (PI) to personalize recommendations for salvage intensity-modulated radiotherapy (IMRT) in patients with locally recurrent nasopharyngeal carcinoma (lrNPC). Methods: Patients with lrNPC from two academic institutions (Sun Yat-Sen University Cancer Center [SYSUCC-A; n = 251 (training cohort)] and National Cancer Centre Singapore [NCCS; n = 114] and SYSUCC-B [n = 193 (validation cohorts)]) underwent salvage treatment with IMRT from 2001 to 2015. Primary and secondary clinical end points were overall survival (OS) and grade 5 toxicity-free rate (G5-TFR), respectively. Covariate inclusion to the PIs was qualified by a multivariable two-sided P < .05. Discrimination and calibration of the PIs were assessed. Results: The primary PI comprised covariates that were adversely associated with OS in the training cohort (gross tumor volumerecurrence hazard ratio [HR], 1.01/mL increase [ P < .001], agerecurrence HR, 1.02/year increase [ P = .008]; repeat IMRT equivalent dose in 2-Gy fractions [EQD2] ≥ 68 Gy HR, 1.42 [ P = .03]; prior radiotherapy-induced grade ≥ 3 toxicities HR, 1.90 [ P = .001]; recurrent tumor [rT]-category 3 to 4 HR, 1.96 [ P = .005]), in ascending order of weight. Discrimination of the PI for OS was comparable between training and both validation cohorts (Harrell’s C = 0.71 [SYSUCC-A], 0.72 [NCCS], and 0.69 [SYSUCC-B]); discretization by using a fixed PI score cutoff of 252 determined from the training data set yielded low- and high-risk subgroups with disparate OS in the validation cohorts (NCCS HR, 3.09 [95% CI, 1.95 to 4.89]; SYSUCC-B HR, 3.80 [95% CI, 2.55 to 5.66]). Our five-factor PI predicted OS and G5-TFR (predicted v observed 36-month OS and G5-TFR, 22% v 15% and 38% v 44% for high-risk NCCS and 26% v 31% and 45% v 46% for high-risk SYSUCC-B). Conclusion: We present a validated PI for robust clinical stratification of radioresistant NPC. Low-risk patients represent ideal candidates for curative repeat IMRT, whereas novel clinical trials are needed in the unfavorable high-risk subgroup.Keywords
This publication has 28 references indexed in Scilit:
- The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRTOral Oncology, 2014
- Evolution of treatment for nasopharyngeal cancer – Success and setback in the intensity-modulated radiotherapy eraRadiotherapy and Oncology, 2014
- External validation of a Cox prognostic model: principles and methodsBMC Medical Research Methodology, 2013
- Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapyEuropean Journal of Cancer, 2012
- Long-term Outcomes and Prognostic Factors of Re-irradiation for Locally Recurrent Nasopharyngeal Carcinoma using Intensity-modulated RadiotherapyClinical Oncology, 2012
- A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinomaRadiotherapy and Oncology, 2012
- The battle against nasopharyngeal cancerRadiotherapy and Oncology, 2012
- Intensity-Modulated Radiation Therapy in the Salvage of Locally Recurrent Nasopharyngeal CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Inflaming Gastrointestinal Oncogenic ProgrammingCancer Cell, 2008
- A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal CarcinomaClinical Cancer Research, 2005